Not yet recruitingPhase 3NCT05698979
Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease
Studying Buerger disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Toulouse
- Principal Investigator
- Julie Malloizel-Delaunay, MDUniversity Hospital, Toulouse
- Intervention
- BOTOX INJECTION(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05698979 on ClinicalTrials.govOther trials for Buerger disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07215923A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy SmokersAntidote Therapeutics, Inc
- ENROLLING BY INVITATIONNCT07023965Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)Beijing Northland Biotech. Co., Ltd.
- RECRUITINGPHASE4NCT05854615Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's DiseaseCell Biopeutics Resources Sdn Bhd